Sanofi Pauses New Allergy Drug Development... OX40 and IL-13 Emerge as Key Players

💡 AI analysis: Sanofi's strategic pivot signals a concentrated R&D reallocation toward OX40 and IL-13 pathways, intensifying the competitive landscape for targeted anti-inflammatory therapies.